{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T07:30:45Z","timestamp":1787729445589,"version":"build-2784847793"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.coph.2016.01.008","type":"journal-article","created":{"date-parts":[[2016,2,16]],"date-time":"2016-02-16T16:54:23Z","timestamp":1455641663000},"page":"38-42","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Pharmacogenetics and oral antithrombotic drugs"],"prefix":"10.1016","volume":"27","author":[{"given":"William L","family":"Baker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel G","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2 Suppl","key":"10.1016\/j.coph.2016.01.008_sbref0005","doi-asserted-by":"crossref","first-page":"e531S","DOI":"10.1378\/chest.11-2304","article-title":"Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines","volume":"141","author":"You","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.coph.2016.01.008_sbref0010","doi-asserted-by":"crossref","first-page":"244","DOI":"10.18553\/jmcp.2009.15.3.244","article-title":"Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States","volume":"15","author":"Baker","year":"2009","journal-title":"J Manag Care Pharm"},{"key":"10.1016\/j.coph.2016.01.008_bib0015","doi-asserted-by":"crossref","first-page":"897","DOI":"10.7326\/0003-4819-120-11-199406010-00001","article-title":"Risk factors for intracranial hemorrhage in outpatients raking warfarin","volume":"120","author":"Hylek","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.coph.2016.01.008_sbref0020","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1124\/pr.112.007252","article-title":"Pharmacogenetics and cardiovascular disease \u2013 implications for personalized medicine","volume":"65","author":"Johnson","year":"2013","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.coph.2016.01.008_bib0025","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1056\/NEJMsa1103053","article-title":"Emergency hospitalizations for adverse drug events in older Americans","volume":"365","author":"Budnitz","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2016.01.008_bib0030","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1002\/phar.1377","article-title":"The changing face of anticoagulation management: an improving countenance","volume":"33","author":"Baker","year":"2013","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.coph.2016.01.008_bib0035","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1055\/s-0037-1614485","article-title":"Vitamin K intake and sensitivity to warfarin in patients consuming regular diets","volume":"81","author":"Lutetsky","year":"1999","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.coph.2016.01.008_bib0040","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nature02254","article-title":"Identification of the gene for vitamin K epoxide reductase","volume":"427","author":"Li","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.coph.2016.01.008_sbref0045","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1146\/annurev-med-101712-122545","article-title":"Applied pharmacogenomics in cardiovascular medicine","volume":"65","author":"Weeke","year":"2014","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.coph.2016.01.008_sbref0050","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1161\/CIRCULATIONAHA.107.737312","article-title":"Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation","volume":"116","author":"Anderson","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.coph.2016.01.008_bib0055","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/jth.12072","article-title":"The VKORC1 and CYP2C9 genotypes are associated with over-anticoagulation during initiation of warfarin therapy in children","volume":"11","author":"Biss","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.coph.2016.01.008_bib0060","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1182\/blood-2008-09-176222","article-title":"Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy","volume":"113","author":"Perez-Andreu","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.coph.2016.01.008_bib0065","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1002\/pbc.24932","article-title":"VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children","volume":"61","author":"Shaw","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.coph.2016.01.008_bib0070","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/GIM.0b013e31815bf924","article-title":"A rapid-ACCE review of CYP2C9 and VKORC1 alleles testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding","volume":"10","author":"McClain","year":"2008","journal-title":"Genet Med"},{"key":"10.1016\/j.coph.2016.01.008_sbref0075","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa0809329","article-title":"Estimation of the warfarin dose with clinical and pharmacogenetic data","volume":"360","author":"Klein","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2016.01.008_bib0080","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1111\/j.1538-7836.2008.03095.x","article-title":"Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients","volume":"6","author":"Lenzini","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.coph.2016.01.008_sbref0085","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/clpt.2011.185","article-title":"Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing","volume":"90","author":"Johnson","year":"2011","journal-title":"Clin Pharmacol Ther"},{"issue":"2 Suppl","key":"10.1016\/j.coph.2016.01.008_bib0090","doi-asserted-by":"crossref","first-page":"e44S","DOI":"10.1378\/chest.11-2292","article-title":"Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines","volume":"141","author":"Ageno","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.coph.2016.01.008_bib0095","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/clpt.2008.10","article-title":"Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin","volume":"84","author":"Gage","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.coph.2016.01.008_bib0100","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/FPC.0b013e328338bac2","article-title":"Extending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP2C9","volume":"20","author":"Sagreiya","year":"2010","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.coph.2016.01.008_sbref0105","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1056\/NEJMoa1311386","article-title":"A randomized trial of genotype-guided dosing of warfarin","volume":"369","author":"Pirmohamed","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2016.01.008_sbref0110","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1056\/NEJMoa1310669","article-title":"A pharmacogenetic versus a clinical algorithm for warfarin dosing","volume":"369","author":"Kimmel","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2016.01.008_bib0115","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/bcp.12475","article-title":"Genotype-guided drug prescribing: a systematic review and meta-analysis of randomized controlled trials","volume":"80","author":"Goulding","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.coph.2016.01.008_sbref0120","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1001\/jamainternmed.2014.2368","article-title":"Genotype-guided vs clinical dosing of warfarin and its analogues: meta-analysis of randomized clinical trials","volume":"174","author":"Stergiopoulos","year":"2014","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.coph.2016.01.008_bib0125","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1161\/CIRCOUTCOMES.112.966572","article-title":"Systematic review and adjusted indirect comparison meta-analysis of oral anticoagulants in atrial fibrillation","volume":"5","author":"Baker","year":"2012","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.coph.2016.01.008_bib0130","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(15)60245-8","article-title":"Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs","volume":"386","author":"Verheugt","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2016.01.008_bib0135","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1161\/CIRCULATIONAHA.112.001233","article-title":"Genetic determinants of dabigatran plasma levels and their relation to bleeding","volume":"127","author":"Pare","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.coph.2016.01.008_bib0140","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1016\/S0140-6736(14)61994-2","article-title":"Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial","volume":"385","author":"Mega","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2016.01.008_bib0145","doi-asserted-by":"crossref","first-page":"09S","DOI":"10.1177\/1076029609343004","article-title":"Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor","volume":"15","author":"Sangier","year":"2009","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.coph.2016.01.008_bib0150","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2016.01.008_bib0155","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1365-2125.2007.02899.x","article-title":"The pharmacokinetics, pharmacodynamics, and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects","volume":"64","author":"Stangier","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.coph.2016.01.008_bib0160","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1007\/s12325-011-0025-1","article-title":"Dabigatran: an oral direct thrombin inhibitor for use in atrial fibrillation","volume":"28","author":"Bendel","year":"2011","journal-title":"Adv Ther"},{"key":"10.1016\/j.coph.2016.01.008_bib0165","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/j.cjca.2013.04.002","article-title":"Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban","volume":"29","author":"Gong","year":"2013","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.coph.2016.01.008_bib0170","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2016.01.008_bib0175","doi-asserted-by":"crossref","first-page":"73","DOI":"10.7326\/0003-4819-150-2-200901200-00005","article-title":"Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation","volume":"150","author":"Eckman","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.coph.2016.01.008_bib0180","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1161\/CIRCOUTCOMES.108.808592","article-title":"Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation","volume":"2","author":"Patrick","year":"2009","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.coph.2016.01.008_bib0185","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/clpt.2013.190","article-title":"Cost-effectiveness of pharmacogenetics-guided warfarin therapy vs. alternative anticoagulation in atrial fibrillation","volume":"95","author":"Pink","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.coph.2016.01.008_bib0190","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1002\/phar.1329","article-title":"Feasibility of implementing a comprehensive warfarin pharmacogenomics service","volume":"33","author":"Nutescu","year":"2013","journal-title":"Pharmacotherapy"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489216300042?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489216300042?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,4]],"date-time":"2022-06-04T08:55:50Z","timestamp":1654332950000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489216300042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":38,"alternative-id":["S1471489216300042"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2016.01.008","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacogenetics and oral antithrombotic drugs","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2016.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}